Detalles de la búsqueda
1.
Comparison of outcomes for Hispanic and non-Hispanic patients with advanced renal cell carcinoma in the International Metastatic Renal Cell Carcinoma Database.
Cancer
; 130(11): 2003-2013, 2024 Jun 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-38297953
2.
Development and Validation of a Prognostic Risk Model for Patients with Advanced Melanoma Treated with Immune Checkpoint Inhibitors.
Oncologist
; 28(9): 812-822, 2023 09 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-37011230
3.
Characterization of Patients With Metastatic Renal Cell Carcinoma Experiencing Complete Response to First-line Therapies: Results From the International Metastatic Renal Cell Carcinoma Database Consortium.
J Urol
; 209(4): 701-709, 2023 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-36573926
4.
Melanoma: An immunotherapy journey from bench to bedside.
Cancer Treat Res
; 183: 49-89, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-35551656
5.
Business as unusual: medical oncology services adapt and deliver during COVID-19.
Intern Med J
; 51(5): 673-681, 2021 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-34047023
6.
Immune checkpoint blockade in solid organ tumours: Choice, dose and predictors of response.
Br J Clin Pharmacol
; 86(9): 1736-1752, 2020 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-32384184
7.
Immunotherapy in renal cell carcinoma.
Lancet Oncol
; 24(11): 1164-1166, 2023 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-37844599
8.
Immune-Related Adverse Events and Survival Among Patients With Metastatic NSCLC Treated With Immune Checkpoint Inhibitors.
JAMA Netw Open
; 7(1): e2352302, 2024 Jan 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-38236598
9.
Mechanisms and clinical implications in renal carcinoma resistance: narrative review of immune checkpoint inhibitors.
Cancer Drug Resist
; 6(2): 416-429, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-37457122
10.
Real-World Treatment Patterns and Effectiveness of Targeted and Immune Checkpoint Inhibitor-Based Systemic Therapy in BRAF Mutation-Positive NSCLC.
JTO Clin Res Rep
; 4(3): 100460, 2023 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-36915629
11.
Treatment-Free Survival After Nivolumab vs Pembrolizumab vs Nivolumab-Ipilimumab for Advanced Melanoma.
JAMA Netw Open
; 6(6): e2319607, 2023 Jun 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-37351883
12.
Impact of Performance Status on Survival Outcomes and Health Care Utilization in Patients With Advanced NSCLC Treated With Immune Checkpoint Inhibitors.
JTO Clin Res Rep
; 4(4): 100482, 2023 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-37090101
13.
Lung Immune Therapy Evaluation (LITE) Risk, a Novel Prognostic Model for Patients With Advanced Non-Small Cell Lung Cancer Treated With Immune Checkpoint Blockade.
Clin Lung Cancer
; 24(3): e152-e159, 2023 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-36774234
14.
CABOSEQ: The Effectiveness of Cabozantinib in Patients With Treatment Refractory Advanced Renal Cell Carcinoma: Results From the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC).
Clin Genitourin Cancer
; 21(1): 106.e1-106.e8, 2023 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-35945133
15.
Outcomes for International Metastatic Renal Cell Carcinoma Database Consortium Prognostic Groups in Contemporary First-line Combination Therapies for Metastatic Renal Cell Carcinoma.
Eur Urol
; 84(1): 109-116, 2023 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-36707357
16.
Characterization of Patients with Metastatic Renal Cell Carcinoma Undergoing Deferred, Upfront, or No Cytoreductive Nephrectomy in the Era of Combination Immunotherapy: Results from the International Metastatic Renal Cell Carcinoma Database Consortium.
Eur Urol Oncol
; 2023 Oct 30.
Artículo
en Inglés
| MEDLINE | ID: mdl-37914579
17.
Find the path of least resistance: Adaptive therapy to delay treatment failure and improve outcomes.
Biochim Biophys Acta Rev Cancer
; 1877(2): 188681, 2022 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-35051527
18.
Treatment Selection in First-line Metastatic Renal Cell Carcinoma-The Contemporary Treatment Paradigm in the Age of Combination Therapy: A Review.
JAMA Oncol
; 8(2): 292-299, 2022 Feb 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-34792538
19.
Association of Immune-Related Adverse Events, Hospitalization, and Therapy Resumption With Survival Among Patients With Metastatic Melanoma Receiving Single-Agent or Combination Immunotherapy.
JAMA Netw Open
; 5(12): e2245596, 2022 12 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-36480204
20.
Imaging Response to Contemporary Immuno-oncology Combination Therapies in Patients With Metastatic Renal Cell Carcinoma.
JAMA Netw Open
; 5(6): e2216379, 2022 06 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-35687336